 Sarah Parker
Concepts (256)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antimicrobial Stewardship | 10 | 2021 | 93 | 5.060 |
Why?
| | Hospitals, Pediatric | 21 | 2022 | 478 | 3.910 |
Why?
| | Anti-Infective Agents | 12 | 2021 | 225 | 3.830 |
Why?
| | Anti-Bacterial Agents | 27 | 2023 | 1484 | 2.870 |
Why?
| | Drug Utilization Review | 6 | 2020 | 57 | 1.770 |
Why?
| | Osteomyelitis | 7 | 2022 | 103 | 1.570 |
Why?
| | Arthritis, Infectious | 6 | 2022 | 50 | 1.520 |
Why?
| | Bacteremia | 2 | 2023 | 159 | 1.450 |
Why?
| | Metronidazole | 3 | 2019 | 19 | 1.340 |
Why?
| | Appendicitis | 3 | 2019 | 108 | 1.260 |
Why?
| | Bacterial Infections | 3 | 2020 | 222 | 1.020 |
Why?
| | Child | 38 | 2023 | 18488 | 1.000 |
Why?
| | Kingella kingae | 2 | 2022 | 8 | 0.960 |
Why?
| | Otitis Media | 3 | 2023 | 142 | 0.960 |
Why?
| | Staphylococcal Infections | 3 | 2023 | 337 | 0.930 |
Why?
| | Acute Disease | 5 | 2023 | 914 | 0.910 |
Why?
| | Respiration, Artificial | 2 | 2022 | 526 | 0.790 |
Why?
| | Musculoskeletal System | 1 | 2022 | 44 | 0.770 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 2 | 2023 | 192 | 0.770 |
Why?
| | Retrospective Studies | 22 | 2023 | 12608 | 0.750 |
Why?
| | Surgical Wound Infection | 1 | 2022 | 250 | 0.660 |
Why?
| | Respiratory Tract Infections | 1 | 2022 | 323 | 0.640 |
Why?
| | Drug Resistance, Bacterial | 3 | 2021 | 156 | 0.620 |
Why?
| | Interdisciplinary Communication | 1 | 2019 | 185 | 0.610 |
Why?
| | Medical Order Entry Systems | 1 | 2018 | 41 | 0.590 |
Why?
| | Cephalosporins | 2 | 2015 | 26 | 0.580 |
Why?
| | Cefoxitin | 1 | 2017 | 8 | 0.580 |
Why?
| | Ceftriaxone | 1 | 2017 | 18 | 0.570 |
Why?
| | beta-Lactams | 1 | 2017 | 27 | 0.560 |
Why?
| | Drug Costs | 1 | 2017 | 91 | 0.560 |
Why?
| | Interprofessional Relations | 1 | 2019 | 258 | 0.560 |
Why?
| | Musculoskeletal Diseases | 1 | 2017 | 55 | 0.560 |
Why?
| | Humans | 54 | 2023 | 115587 | 0.550 |
Why?
| | Prescriptions | 1 | 2016 | 60 | 0.540 |
Why?
| | Communicable Diseases | 4 | 2021 | 130 | 0.540 |
Why?
| | Pyomyositis | 3 | 2022 | 13 | 0.540 |
Why?
| | Infant | 15 | 2023 | 7979 | 0.530 |
Why?
| | Neutropenia | 1 | 2016 | 127 | 0.510 |
Why?
| | Exanthema | 1 | 2016 | 77 | 0.510 |
Why?
| | Inpatients | 4 | 2021 | 380 | 0.500 |
Why?
| | Decision Support Systems, Clinical | 1 | 2018 | 179 | 0.500 |
Why?
| | Diarrhea | 1 | 2016 | 173 | 0.500 |
Why?
| | Health Resources | 1 | 2016 | 122 | 0.480 |
Why?
| | Electronic Health Records | 2 | 2019 | 805 | 0.480 |
Why?
| | Enterovirus D, Human | 1 | 2016 | 72 | 0.480 |
Why?
| | Child, Preschool | 13 | 2021 | 9133 | 0.450 |
Why?
| | Enterovirus Infections | 1 | 2016 | 160 | 0.440 |
Why?
| | Pandemics | 2 | 2022 | 1334 | 0.440 |
Why?
| | Guideline Adherence | 1 | 2017 | 497 | 0.440 |
Why?
| | Disease Outbreaks | 1 | 2016 | 308 | 0.440 |
Why?
| | Inappropriate Prescribing | 1 | 2013 | 52 | 0.440 |
Why?
| | Referral and Consultation | 1 | 2017 | 646 | 0.410 |
Why?
| | Health Personnel | 1 | 2018 | 581 | 0.410 |
Why?
| | Blood Culture | 2 | 2021 | 9 | 0.390 |
Why?
| | Microbial Sensitivity Tests | 4 | 2022 | 299 | 0.370 |
Why?
| | Vancomycin | 2 | 2023 | 76 | 0.360 |
Why?
| | Liver Abscess, Amebic | 2 | 2009 | 3 | 0.350 |
Why?
| | Practice Guidelines as Topic | 1 | 2017 | 1405 | 0.340 |
Why?
| | Phospholipases A | 2 | 2007 | 101 | 0.340 |
Why?
| | Stomach Rupture | 1 | 2009 | 2 | 0.330 |
Why?
| | Phospholipases | 1 | 2009 | 13 | 0.330 |
Why?
| | Thiolester Hydrolases | 1 | 2009 | 9 | 0.330 |
Why?
| | Pericardial Effusion | 1 | 2009 | 21 | 0.320 |
Why?
| | Pleural Effusion | 1 | 2009 | 46 | 0.320 |
Why?
| | Mycobacterium tuberculosis | 2 | 2009 | 271 | 0.320 |
Why?
| | Colorado | 4 | 2020 | 4113 | 0.320 |
Why?
| | Lactones | 1 | 2009 | 56 | 0.310 |
Why?
| | Peritonitis | 1 | 2009 | 76 | 0.310 |
Why?
| | Drug Utilization | 3 | 2017 | 167 | 0.300 |
Why?
| | Carboxylic Ester Hydrolases | 1 | 2007 | 16 | 0.290 |
Why?
| | Cost Savings | 2 | 2017 | 75 | 0.280 |
Why?
| | Staphylococcus aureus | 4 | 2023 | 385 | 0.280 |
Why?
| | Gene Expression Regulation, Bacterial | 1 | 2009 | 284 | 0.280 |
Why?
| | Dermatomycoses | 1 | 2006 | 9 | 0.270 |
Why?
| | Pharmacy Service, Hospital | 2 | 2017 | 84 | 0.270 |
Why?
| | Drug Approval | 1 | 2006 | 78 | 0.260 |
Why?
| | Mycobacterium | 1 | 2007 | 103 | 0.260 |
Why?
| | Immunoglobulins, Intravenous | 1 | 2006 | 123 | 0.250 |
Why?
| | Bacterial Proteins | 2 | 2018 | 739 | 0.250 |
Why?
| | Thimerosal | 1 | 2004 | 4 | 0.240 |
Why?
| | Preservatives, Pharmaceutical | 1 | 2004 | 24 | 0.240 |
Why?
| | Encephalitis, Viral | 1 | 2004 | 39 | 0.240 |
Why?
| | Simplexvirus | 1 | 2004 | 82 | 0.230 |
Why?
| | Herpes Simplex | 1 | 2004 | 88 | 0.230 |
Why?
| | Infection Control | 2 | 2015 | 136 | 0.230 |
Why?
| | Lymphadenitis | 1 | 2023 | 4 | 0.220 |
Why?
| | Male | 17 | 2021 | 55949 | 0.220 |
Why?
| | Cross Infection | 2 | 2015 | 202 | 0.220 |
Why?
| | Drug Administration Schedule | 3 | 2017 | 724 | 0.210 |
Why?
| | Adolescent | 10 | 2023 | 17889 | 0.210 |
Why?
| | Cephalexin | 1 | 2022 | 8 | 0.210 |
Why?
| | Immunotherapy | 1 | 2006 | 479 | 0.200 |
Why?
| | Autistic Disorder | 1 | 2004 | 163 | 0.200 |
Why?
| | Exudates and Transudates | 1 | 2021 | 12 | 0.200 |
Why?
| | Fluoroquinolones | 1 | 2021 | 41 | 0.190 |
Why?
| | Risk Adjustment | 1 | 2021 | 75 | 0.190 |
Why?
| | Antibiotic Prophylaxis | 1 | 2022 | 96 | 0.190 |
Why?
| | Fever | 2 | 2017 | 280 | 0.190 |
Why?
| | Female | 15 | 2021 | 59913 | 0.190 |
Why?
| | Bone Diseases, Infectious | 1 | 2020 | 8 | 0.180 |
Why?
| | Databases, Factual | 3 | 2023 | 1138 | 0.180 |
Why?
| | Meningitis | 1 | 2021 | 74 | 0.180 |
Why?
| | Laboratories | 1 | 2021 | 95 | 0.180 |
Why?
| | Time Factors | 3 | 2021 | 6165 | 0.180 |
Why?
| | Treatment Outcome | 6 | 2017 | 9159 | 0.170 |
Why?
| | Molecular Diagnostic Techniques | 2 | 2020 | 91 | 0.170 |
Why?
| | Appendectomy | 2 | 2017 | 60 | 0.170 |
Why?
| | Bacteroides fragilis | 1 | 2019 | 11 | 0.170 |
Why?
| | Trachea | 1 | 2021 | 233 | 0.170 |
Why?
| | Antibodies, Monoclonal | 1 | 2006 | 1265 | 0.170 |
Why?
| | Encephalitis | 1 | 2021 | 127 | 0.170 |
Why?
| | Monte Carlo Method | 1 | 2019 | 140 | 0.170 |
Why?
| | Neisseriaceae Infections | 1 | 2018 | 5 | 0.160 |
Why?
| | Hospitals | 2 | 2021 | 585 | 0.160 |
Why?
| | Area Under Curve | 1 | 2019 | 278 | 0.160 |
Why?
| | Entamoeba histolytica | 2 | 2009 | 7 | 0.160 |
Why?
| | Hospital Records | 1 | 2018 | 11 | 0.160 |
Why?
| | Medical Records Systems, Computerized | 1 | 2018 | 90 | 0.150 |
Why?
| | Patient Readmission | 3 | 2017 | 609 | 0.150 |
Why?
| | Hydrolysis | 2 | 2009 | 179 | 0.150 |
Why?
| | Infant, Newborn | 5 | 2021 | 5077 | 0.150 |
Why?
| | Sequence Homology, Amino Acid | 2 | 2009 | 352 | 0.150 |
Why?
| | Central Venous Catheters | 1 | 2017 | 39 | 0.140 |
Why?
| | Administration, Oral | 2 | 2016 | 734 | 0.140 |
Why?
| | Abdominal Abscess | 1 | 2017 | 23 | 0.140 |
Why?
| | Abscess | 1 | 2017 | 72 | 0.140 |
Why?
| | Intensive Care Units, Pediatric | 1 | 2018 | 147 | 0.140 |
Why?
| | Drug Substitution | 1 | 2017 | 46 | 0.140 |
Why?
| | Medical Records | 1 | 2017 | 157 | 0.140 |
Why?
| | Length of Stay | 2 | 2020 | 958 | 0.140 |
Why?
| | Communicable Disease Control | 1 | 2017 | 66 | 0.140 |
Why?
| | Pharmacists | 1 | 2019 | 237 | 0.140 |
Why?
| | Drug Resistance | 1 | 2017 | 162 | 0.140 |
Why?
| | Osteoarthritis | 1 | 2018 | 173 | 0.140 |
Why?
| | Drug Prescriptions | 1 | 2018 | 241 | 0.140 |
Why?
| | Urinary Tract Infections | 1 | 2017 | 136 | 0.130 |
Why?
| | Hospitalization | 3 | 2023 | 1765 | 0.130 |
Why?
| | Administration, Intravenous | 1 | 2016 | 126 | 0.130 |
Why?
| | Amino Acid Sequence | 3 | 2009 | 2000 | 0.130 |
Why?
| | Knowledge Management | 1 | 2014 | 2 | 0.120 |
Why?
| | Clostridium Infections | 1 | 2015 | 56 | 0.120 |
Why?
| | Drug Monitoring | 1 | 2016 | 184 | 0.120 |
Why?
| | Acute Kidney Injury | 1 | 2021 | 646 | 0.120 |
Why?
| | Molecular Sequence Data | 3 | 2009 | 2790 | 0.120 |
Why?
| | Postoperative Care | 1 | 2016 | 222 | 0.120 |
Why?
| | Cost-Benefit Analysis | 1 | 2017 | 548 | 0.120 |
Why?
| | Drug Therapy, Combination | 1 | 2017 | 962 | 0.120 |
Why?
| | Tomography, X-Ray Computed | 3 | 2009 | 2392 | 0.110 |
Why?
| | Medication Therapy Management | 1 | 2014 | 67 | 0.110 |
Why?
| | Risk Assessment | 2 | 2016 | 2987 | 0.110 |
Why?
| | United States | 7 | 2021 | 12295 | 0.110 |
Why?
| | Laparoscopy | 1 | 2017 | 400 | 0.110 |
Why?
| | Quality of Health Care | 1 | 2017 | 576 | 0.110 |
Why?
| | Drug Hypersensitivity | 1 | 2013 | 86 | 0.100 |
Why?
| | Bacteria | 3 | 2023 | 729 | 0.100 |
Why?
| | Prospective Studies | 2 | 2022 | 6264 | 0.100 |
Why?
| | Physicians | 1 | 2019 | 776 | 0.090 |
Why?
| | Cohort Studies | 2 | 2017 | 4944 | 0.090 |
Why?
| | Attitude of Health Personnel | 1 | 2017 | 990 | 0.090 |
Why?
| | Sensitivity and Specificity | 2 | 2023 | 1718 | 0.090 |
Why?
| | Practice Patterns, Physicians' | 1 | 2018 | 1180 | 0.090 |
Why?
| | Pediatrics | 2 | 2015 | 986 | 0.080 |
Why?
| | Paromomycin | 1 | 2009 | 2 | 0.080 |
Why?
| | Mycolic Acids | 1 | 2009 | 6 | 0.080 |
Why?
| | Trophozoites | 1 | 2009 | 4 | 0.080 |
Why?
| | Antiprotozoal Agents | 1 | 2009 | 12 | 0.080 |
Why?
| | Cell Wall | 1 | 2009 | 50 | 0.080 |
Why?
| | DNA, Protozoan | 1 | 2008 | 26 | 0.080 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2017 | 1870 | 0.080 |
Why?
| | Young Adult | 3 | 2021 | 10470 | 0.080 |
Why?
| | Drainage | 1 | 2009 | 151 | 0.080 |
Why?
| | Tuberculosis, Pulmonary | 1 | 2009 | 112 | 0.080 |
Why?
| | Terminology as Topic | 1 | 2009 | 186 | 0.080 |
Why?
| | Antitubercular Agents | 1 | 2009 | 170 | 0.070 |
Why?
| | Nitrobenzenes | 1 | 2007 | 13 | 0.070 |
Why?
| | Chromatography, Thin Layer | 1 | 2007 | 24 | 0.070 |
Why?
| | Polysorbates | 1 | 2007 | 35 | 0.070 |
Why?
| | Genotype | 2 | 2009 | 1786 | 0.070 |
Why?
| | Injections, Intravenous | 2 | 2017 | 204 | 0.070 |
Why?
| | Membrane Lipids | 1 | 2007 | 87 | 0.070 |
Why?
| | Selection, Genetic | 1 | 2008 | 243 | 0.070 |
Why?
| | Risk Factors | 2 | 2016 | 8697 | 0.070 |
Why?
| | Maximum Tolerated Dose | 1 | 2006 | 182 | 0.070 |
Why?
| | Recombinant Proteins | 1 | 2009 | 1243 | 0.060 |
Why?
| | Enzyme Inhibitors | 1 | 2009 | 757 | 0.060 |
Why?
| | United States Food and Drug Administration | 1 | 2006 | 173 | 0.060 |
Why?
| | Escherichia coli | 1 | 2009 | 730 | 0.060 |
Why?
| | Ethylmercury Compounds | 1 | 2004 | 1 | 0.060 |
Why?
| | Diphtheria-Tetanus Vaccine | 1 | 2004 | 4 | 0.060 |
Why?
| | Methylmercury Compounds | 1 | 2004 | 6 | 0.060 |
Why?
| | Diphtheria-Tetanus-Pertussis Vaccine | 1 | 2004 | 25 | 0.060 |
Why?
| | Diagnosis, Differential | 1 | 2009 | 1357 | 0.060 |
Why?
| | Aphasia | 1 | 2004 | 19 | 0.060 |
Why?
| | Reproducibility of Results | 2 | 2023 | 2800 | 0.060 |
Why?
| | Hematologic Neoplasms | 1 | 2006 | 136 | 0.060 |
Why?
| | Streptococcus pyogenes | 1 | 2004 | 33 | 0.060 |
Why?
| | Half-Life | 1 | 2004 | 145 | 0.060 |
Why?
| | Acyclovir | 1 | 2004 | 100 | 0.060 |
Why?
| | Child Development Disorders, Pervasive | 1 | 2004 | 57 | 0.060 |
Why?
| | Vomiting | 1 | 2004 | 125 | 0.060 |
Why?
| | Adult | 4 | 2021 | 30718 | 0.060 |
Why?
| | Kinetics | 1 | 2007 | 1569 | 0.060 |
Why?
| | Pneumonia | 1 | 2009 | 576 | 0.060 |
Why?
| | Haemophilus influenzae | 1 | 2023 | 50 | 0.060 |
Why?
| | Ampicillin | 1 | 2023 | 13 | 0.050 |
Why?
| | Nasopharynx | 1 | 2023 | 63 | 0.050 |
Why?
| | Multiplex Polymerase Chain Reaction | 1 | 2023 | 45 | 0.050 |
Why?
| | Cefadroxil | 1 | 2022 | 6 | 0.050 |
Why?
| | Cephalothin | 1 | 2022 | 6 | 0.050 |
Why?
| | Oxacillin | 1 | 2022 | 6 | 0.050 |
Why?
| | Methicillin | 1 | 2022 | 11 | 0.050 |
Why?
| | Cefazolin | 1 | 2022 | 18 | 0.050 |
Why?
| | Streptococcus pneumoniae | 1 | 2023 | 133 | 0.050 |
Why?
| | Developmental Disabilities | 1 | 2004 | 240 | 0.050 |
Why?
| | Seizures | 1 | 2004 | 344 | 0.050 |
Why?
| | Microbiology | 1 | 2021 | 17 | 0.050 |
Why?
| | Reference Standards | 1 | 2021 | 161 | 0.050 |
Why?
| | Staining and Labeling | 1 | 2021 | 139 | 0.050 |
Why?
| | Myositis | 1 | 2020 | 44 | 0.040 |
Why?
| | Feces | 2 | 2015 | 372 | 0.040 |
Why?
| | Cross-Sectional Studies | 2 | 2021 | 4435 | 0.040 |
Why?
| | Diagnostic Errors | 1 | 2020 | 151 | 0.040 |
Why?
| | Clindamycin | 1 | 2018 | 12 | 0.040 |
Why?
| | Hospital Charges | 1 | 2018 | 39 | 0.040 |
Why?
| | Research Design | 1 | 2004 | 946 | 0.040 |
Why?
| | Methyltransferases | 1 | 2018 | 61 | 0.040 |
Why?
| | Animals | 3 | 2009 | 32102 | 0.040 |
Why?
| | Arthritis, Rheumatoid | 1 | 2006 | 1002 | 0.040 |
Why?
| | Controlled Before-After Studies | 1 | 2017 | 13 | 0.040 |
Why?
| | Age Distribution | 1 | 2018 | 341 | 0.040 |
Why?
| | Sex Distribution | 1 | 2018 | 337 | 0.040 |
Why?
| | Benchmarking | 1 | 2018 | 163 | 0.040 |
Why?
| | Lung | 1 | 2009 | 3672 | 0.030 |
Why?
| | Early Diagnosis | 1 | 2016 | 220 | 0.030 |
Why?
| | Algorithms | 1 | 2023 | 1490 | 0.030 |
Why?
| | Recurrence | 1 | 2017 | 952 | 0.030 |
Why?
| | Kidney | 1 | 2021 | 1207 | 0.030 |
Why?
| | Inservice Training | 1 | 2014 | 107 | 0.030 |
Why?
| | Medical Oncology | 1 | 2015 | 230 | 0.030 |
Why?
| | Asthma | 1 | 2006 | 2066 | 0.030 |
Why?
| | Combined Modality Therapy | 1 | 2016 | 1127 | 0.030 |
Why?
| | Brain | 1 | 2004 | 2370 | 0.030 |
Why?
| | Mice | 1 | 2006 | 15052 | 0.020 |
Why?
| | Patient Discharge | 1 | 2016 | 770 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2021 | 4665 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2015 | 3022 | 0.020 |
Why?
| | Dysentery, Amebic | 1 | 2008 | 1 | 0.020 |
Why?
| | Postoperative Complications | 1 | 2016 | 2161 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2008 | 1000 | 0.020 |
Why?
| | Prophages | 1 | 2004 | 4 | 0.020 |
Why?
| | Substrate Specificity | 1 | 2004 | 357 | 0.010 |
Why?
| | Structure-Activity Relationship | 1 | 2004 | 511 | 0.010 |
Why?
| | Alleles | 1 | 2004 | 794 | 0.010 |
Why?
| | Base Sequence | 1 | 2004 | 2114 | 0.010 |
Why?
| | Aged | 1 | 2009 | 19251 | 0.010 |
Why?
| | Middle Aged | 1 | 2009 | 26999 | 0.010 |
Why?
|
|
Parker's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|